...expression of SSTR2 and SSTR5 in GEP-NEN and investigated the efficacy and safety of octreotide long-acting release (LAR) in the treatment of advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET)...SSTR5 positive expression also predicted improved survival compared with negative expression (the median OS times were NR and 7.22 years, respectively; χ2=6.396, P=0.011) (Fig. 2)…All 54 patients that received octreotide LAR were followed up for a period of 3.2–164.5 months, with a median follow-up period of 31.8 months...three patients achieved partial remission (PR), with the ORR being 5.6% (95% CI, 0.0–11.7%). A total of 43 patients achieved SD, with the SD rate being 79.6% (95% CI, 68.9–90.4%) and 8 patients demonstrated PD. At the conclusion of follow-up, there were still three patients achieving PR, 26 patients achieving SD and 25 patients demonstrating PD.